---
schema_version: "secwatch.filing_event.v1"
accession: "0001604821-26-000015"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2026-08-06T20:05:21+00:00"
generated_at: "2026-08-06T20:10:26.133751+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Natera Q2 revenue $752.8M (+37.7% YoY); raises FY2026 guidance by $100M

## Summary
- Revenue $752.8M (+37.7% YoY); tests processed 1,043,900 (+22.4%); oncology tests 296,700 (+57.2%).
- Net loss $67.0M ($0.47 diluted EPS) vs $100.9M ($0.74) in Q2 2025; operating loss $75.8M vs $110.4M.
- Raised 2026 annual revenue guidance by $100M midpoint to $2.85B-$2.91B; gross margin ~64-66%.
- Cash increased $3.6M in Q2 to $1,091.5M; debt $80.3M under UBS line at SOFR+50bps.
- CEO cites Signatera regulatory approvals, Medicare coverage for Prospera, and Panorama NIPT launch.

## SEC filing metadata
- accession: 0001604821-26-000015
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2026-08-06T20:05:21+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000160482126000015/0001604821-26-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000160482126000015/ntra-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001604821-26-000015
- JSON: https://secwatch.observer/filing/0001604821-26-000015.json
- Plain text: https://secwatch.observer/filing/0001604821-26-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.